MERIDIAN BIOSCIENCE INC (VIVO) Stock Fundamental Analysis
USA - NASDAQ:VIVO - US5895841014 - Common Stock
33.97 USD
0 (0%)
33.99 USD
+0.02 (+0.06%)
We assign a fundamental rating of 6 out of 10 to VIVO. VIVO was compared to 189 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making VIVO a very profitable company, without any liquidiy or solvency issues. VIVO has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
VIVO had positive earnings in the past year.
VIVO had a positive operating cash flow in the past year.
VIVO had positive earnings in each of the past 5 years.
VIVO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 9.17%, VIVO belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
With an excellent Return On Equity value of 11.54%, VIVO belongs to the best of the industry, outperforming 87.50% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 14.66%, VIVO belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for VIVO is significantly above the industry average of 9.01%.
The last Return On Invested Capital (14.66%) for VIVO is well below the 3 year average (49.65%), which needs to be investigated, but indicates that VIVO had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROIC | 14.66% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
1.3 Margins
VIVO has a better Profit Margin (12.75%) than 87.04% of its industry peers.
In the last couple of years the Profit Margin of VIVO has grown nicely.
The Operating Margin of VIVO (22.70%) is better than 93.52% of its industry peers.
In the last couple of years the Operating Margin of VIVO has remained more or less at the same level.
VIVO has a Gross Margin (56.56%) which is in line with its industry peers.
In the last couple of years the Gross Margin of VIVO has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% |
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so VIVO is creating value.
The number of shares outstanding for VIVO has been increased compared to 1 year ago.
Compared to 1 year ago, VIVO has an improved debt to assets ratio.
2.2 Solvency
VIVO has an Altman-Z score of 11.77. This indicates that VIVO is financially healthy and has little risk of bankruptcy at the moment.
VIVO has a Altman-Z score of 11.77. This is amongst the best in the industry. VIVO outperforms 88.89% of its industry peers.
The Debt to FCF ratio of VIVO is 0.34, which is an excellent value as it means it would take VIVO, only 0.34 years of fcf income to pay off all of its debts.
VIVO's Debt to FCF ratio of 0.34 is amongst the best of the industry. VIVO outperforms 93.52% of its industry peers.
VIVO has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of VIVO (0.07) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.34 | ||
| Altman-Z | 11.77 |
ROIC/WACC1.53
WACC9.57%
2.3 Liquidity
VIVO has a Current Ratio of 3.63. This indicates that VIVO is financially healthy and has no problem in meeting its short term obligations.
VIVO's Current ratio of 3.63 is in line compared to the rest of the industry. VIVO outperforms 50.00% of its industry peers.
VIVO has a Quick Ratio of 2.46. This indicates that VIVO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.46, VIVO perfoms like the industry average, outperforming 45.83% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 |
3. Growth
3.1 Past
The earnings per share for VIVO have decreased strongly by -17.86% in the last year.
VIVO shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 15.21% yearly.
VIVO shows a small growth in Revenue. In the last year, the Revenue has grown by 4.76%.
Measured over the past years, VIVO shows a quite strong growth in Revenue. The Revenue has been growing by 10.65% on average per year.
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 24.62, VIVO is valued on the expensive side.
Based on the Price/Earnings ratio, VIVO is valued cheaply inside the industry as 83.80% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.08, VIVO is valued at the same level.
Based on the Price/Forward Earnings ratio of 40.37, the valuation of VIVO can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of VIVO indicates a somewhat cheap valuation: VIVO is cheaper than 75.93% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.09. VIVO is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of VIVO indicates a rather cheap valuation: VIVO is cheaper than 86.57% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of VIVO indicates a rather cheap valuation: VIVO is cheaper than 94.44% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 20.27 | ||
| EV/EBITDA | 15.62 |
4.3 Compensation for Growth
The excellent profitability rating of VIVO may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)1.62
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
VIVO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
33.97
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners2.73%
Ins Owner Change0%
Market Cap1.49B
Revenue(TTM)333.02M
Net Income(TTM)42.46M
Analysts43.33
Price Target34.68 (2.09%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)17.65%
Min EPS beat(2)-1.96%
Max EPS beat(2)37.25%
EPS beat(4)3
Avg EPS beat(4)27.19%
Min EPS beat(4)-1.96%
Max EPS beat(4)37.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.54%
Min Revenue beat(2)-4.52%
Max Revenue beat(2)-0.56%
Revenue beat(4)2
Avg Revenue beat(4)6.92%
Min Revenue beat(4)-4.52%
Max Revenue beat(4)23.21%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-4.62%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-5.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.62 | ||
| Fwd PE | 40.37 | ||
| P/S | 4.49 | ||
| P/FCF | 20.27 | ||
| P/OCF | 18.15 | ||
| P/B | 4.06 | ||
| P/tB | 8.42 | ||
| EV/EBITDA | 15.62 |
EPS(TTM)1.38
EY4.06%
EPS(NY)0.84
Fwd EY2.48%
FCF(TTM)1.68
FCFY4.93%
OCF(TTM)1.87
OCFY5.51%
SpS7.57
BVpS8.36
TBVpS4.04
PEG (NY)N/A
PEG (5Y)1.62
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.17% | ||
| ROE | 11.54% | ||
| ROCE | N/A | ||
| ROIC | 14.66% | ||
| ROICexc | 18.35% | ||
| ROICexgc | 44.57% | ||
| OM | 22.7% | ||
| PM (TTM) | 12.75% | ||
| GM | 56.56% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)49.65%
ROIC(5y)N/A
ROICexc(3y)19.62%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y10.61%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y13.29%
ROICexc growth 5Y-2.41%
OM growth 3Y5.46%
OM growth 5Y0.35%
PM growth 3Y1.65%
PM growth 5Y3.46%
GM growth 3Y-1.43%
GM growth 5Y-1.79%
F-Score5
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | 0.34 | ||
| Debt/EBITDA | 0.27 | ||
| Cap/Depr | 52.18% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | 173.69% | ||
| Current Ratio | 3.63 | ||
| Quick Ratio | 2.46 | ||
| Altman-Z | 11.77 |
F-Score5
WACC9.57%
ROIC/WACC1.53
Cap/Depr(3y)65.44%
Cap/Depr(5y)57.5%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)112.8%
Profit Quality(5y)119.92%
High Growth Momentum
Growth
EPS 1Y (TTM)-17.86%
EPS 3Y26.61%
EPS 5Y15.21%
EPS Q2Q%-12.5%
EPS Next Y-39.02%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.76%
Revenue growth 3Y18.33%
Revenue growth 5Y10.65%
Sales Q2Q%-13.82%
Revenue Next Year-13.66%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.75%
EBIT growth 3Y24.79%
EBIT growth 5Y11.03%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.89%
FCF growth 3Y31.57%
FCF growth 5Y14.86%
OCF growth 1Y23.18%
OCF growth 3Y31.55%
OCF growth 5Y14.77%
MERIDIAN BIOSCIENCE INC / VIVO FAQ
Can you provide the ChartMill fundamental rating for MERIDIAN BIOSCIENCE INC?
ChartMill assigns a fundamental rating of 4 / 10 to VIVO.
What is the valuation status for VIVO stock?
ChartMill assigns a valuation rating of 3 / 10 to MERIDIAN BIOSCIENCE INC (VIVO). This can be considered as Overvalued.
Can you provide the profitability details for MERIDIAN BIOSCIENCE INC?
MERIDIAN BIOSCIENCE INC (VIVO) has a profitability rating of 4 / 10.
What is the valuation of MERIDIAN BIOSCIENCE INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for MERIDIAN BIOSCIENCE INC (VIVO) is 24.62 and the Price/Book (PB) ratio is 4.06.
What is the earnings growth outlook for MERIDIAN BIOSCIENCE INC?
The Earnings per Share (EPS) of MERIDIAN BIOSCIENCE INC (VIVO) is expected to decline by -39.02% in the next year.